Global Recombinant Human EGF

Recombinant Human EGF Comprehensive Study by Application (Pharmaceuticals, Cosmetics, Others), Category (Heparin-binding EGF-like growth factor (HB-EGF), Amphiregulin (AR), Epiregulin (EPR), Transforming Growth Factor-α (TGF-α), Others), Indication (Wound Healing, Gastrointestinal Ulceration, Brain Tumor Therapy, Others), Form (Lyophilized Powder, Liquid, Others), Purity (98% SDS-PAGE, 95%-98% SDS-PAGE, <95% SDS-PAGE) Players and Region - Global Market Outlook to 2027

Recombinant Human EGF Market by XX Submarkets | Forecast Years 2020-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Recombinant Human EGF?
Human epidermal growth factor (hEGF) has gotten a lot of press recently because of its potential to speed up the healing of severe injuries including cuts, burns, and diabetic ulcers. Despite its potential clinical usefulness, hEGF is now limited to the treatment of persistent diabetic ulcers due to its high manufacturing cost. hEGF has been found in a variety of prokaryotic and eukaryotic organisms, including E. coli, yeast, rice, and tobacco. Furthermore, it has been shown that the bioactive hEGF protein is substantially expressed in tobacco hairy roots, indicating the possibility of expressing hEGF protein in the hairy root production system. Cell proliferation, cytotoxicity, chemotaxis, calcium flux, secondary cytokine up-regulation, stimulation of surface antigen expression, antiviral, and protease tests are among the recombinant protein activities tested in-house.

AttributesDetails
Study Period2015-2027
Base Year2019
UnitValue (USD Million)
Key Companies ProfiledFUJIFILM Irvine Scientific (United States), PeproTech, Inc (United Kingdom), RandD Systems (Bio-Techne) (United States), Miltenyi Biotec (Germany), Thermo Fisher Scientific (United States), Abcam PLC (United Kingdom), STEMCELL Technologies (Canada), RayBiotech, Inc (United States), Prospec-Tany (Israel) and ScienCell Research Laboratories (United States)


The study covers a detailed analysis segmented by key business segments i.e. , by application (Pharmaceuticals, Cosmetics and Others) and major geographies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Recombinant Human EGF market throughout the predicted period.

The competition is expected to become even more intense in the years to come due to the entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Recombinant Human EGF market report suggests strategies that Players can follow and highlights key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, some of them are FUJIFILM Irvine Scientific (United States), PeproTech, Inc (United Kingdom), RandD Systems (Bio-Techne) (United States), Miltenyi Biotec (Germany), Thermo Fisher Scientific (United States), Abcam PLC (United Kingdom), STEMCELL Technologies (Canada), RayBiotech, Inc (United States), Prospec-Tany (Israel) and ScienCell Research Laboratories (United States).

The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth.

Recombinant Human EGF Market Dynamics:
AttributesDetails
Growth Drivers
  • Growth in Biotechnology Industry
  • Prevalence of Chronic Injuries
Major Trends
  • High Investments in Biotech R&D
Restraints
  • Low Level of Bioavailability & Stability
  • High initial Investments
Road Blocks / Challenges
  • Fierce Competitive Pressure
  • Lack of Regulations
Gaps & Opportunities
  • Increasing Biotech Infrastructure Across Emerging Regions


Key highlights of the Global Recombinant Human EGF market Study:
• CAGR of the market during the forecast period 2019-2027
• In-depth information on growth factors that will accelerate the Recombinant Human EGF market in next few years.
• Detailed Insights on futuristic trends and changing consumer behavior
• Forecast of the Global Recombinant Human EGF market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Recombinant Human EGF Players

Transformation and Important Triggers:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Recombinant Human EGF market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, and SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Recombinant Human EGF market.
In order to make a priority list sorting is done based on revenue generated based on the latest reporting, using paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes Recombinant Human EGF Manufactures, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases, etc.

Report Objectives / Segmentation Covered

By Application
  • Pharmaceuticals
  • Cosmetics
  • Others
By Category
  • Heparin-binding EGF-like growth factor (HB-EGF)
  • Amphiregulin (AR)
  • Epiregulin (EPR)
  • Transforming Growth Factor-α (TGF-α)
  • Others

By Indication
  • Wound Healing
  • Gastrointestinal Ulceration
  • Brain Tumor Therapy
  • Others

By Form
  • Lyophilized Powder
  • Liquid
  • Others

By Purity
  • 98% SDS-PAGE
  • 95%-98% SDS-PAGE
  • <95% SDS-PAGE

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growth in Biotechnology Industry
      • 3.2.2. Prevalence of Chronic Injuries
    • 3.3. Market Challenges
      • 3.3.1. Fierce Competitive Pressure
      • 3.3.2. Lack of Regulations
    • 3.4. Market Trends
      • 3.4.1. High Investments in Biotech R&D
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Recombinant Human EGF, by Application, Category, Indication, Form, Purity and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Recombinant Human EGF (Value)
      • 5.2.1. Global Recombinant Human EGF by: Application (Value)
        • 5.2.1.1. Pharmaceuticals
        • 5.2.1.2. Cosmetics
        • 5.2.1.3. Others
      • 5.2.2. Global Recombinant Human EGF by: Category (Value)
        • 5.2.2.1. Heparin-binding EGF-like growth factor (HB-EGF)
        • 5.2.2.2. Amphiregulin (AR)
        • 5.2.2.3. Epiregulin (EPR)
        • 5.2.2.4. Transforming Growth Factor-α (TGF-α)
        • 5.2.2.5. Others
      • 5.2.3. Global Recombinant Human EGF by: Indication (Value)
        • 5.2.3.1. Wound Healing
        • 5.2.3.2. Gastrointestinal Ulceration
        • 5.2.3.3. Brain Tumor Therapy
        • 5.2.3.4. Others
      • 5.2.4. Global Recombinant Human EGF by: Form (Value)
        • 5.2.4.1. Lyophilized Powder
        • 5.2.4.2. Liquid
        • 5.2.4.3. Others
      • 5.2.5. Global Recombinant Human EGF by: Purity (Value)
        • 5.2.5.1. 98% SDS-PAGE
        • 5.2.5.2. 95%-98% SDS-PAGE
        • 5.2.5.3. <95% SDS-PAGE
      • 5.2.6. Global Recombinant Human EGF Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Recombinant Human EGF: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. FUJIFILM Irvine Scientific (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. PeproTech, Inc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. RandD Systems (Bio-Techne) (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Miltenyi Biotec (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Thermo Fisher Scientific (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Abcam PLC (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. STEMCELL Technologies (Canada)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. RayBiotech, Inc (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Prospec-Tany (Israel)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. ScienCell Research Laboratories (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Recombinant Human EGF Sale, by Application, Category, Indication, Form, Purity and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Recombinant Human EGF (Value)
      • 7.2.1. Global Recombinant Human EGF by: Application (Value)
        • 7.2.1.1. Pharmaceuticals
        • 7.2.1.2. Cosmetics
        • 7.2.1.3. Others
      • 7.2.2. Global Recombinant Human EGF by: Category (Value)
        • 7.2.2.1. Heparin-binding EGF-like growth factor (HB-EGF)
        • 7.2.2.2. Amphiregulin (AR)
        • 7.2.2.3. Epiregulin (EPR)
        • 7.2.2.4. Transforming Growth Factor-α (TGF-α)
        • 7.2.2.5. Others
      • 7.2.3. Global Recombinant Human EGF by: Indication (Value)
        • 7.2.3.1. Wound Healing
        • 7.2.3.2. Gastrointestinal Ulceration
        • 7.2.3.3. Brain Tumor Therapy
        • 7.2.3.4. Others
      • 7.2.4. Global Recombinant Human EGF by: Form (Value)
        • 7.2.4.1. Lyophilized Powder
        • 7.2.4.2. Liquid
        • 7.2.4.3. Others
      • 7.2.5. Global Recombinant Human EGF by: Purity (Value)
        • 7.2.5.1. 98% SDS-PAGE
        • 7.2.5.2. 95%-98% SDS-PAGE
        • 7.2.5.3. <95% SDS-PAGE
      • 7.2.6. Global Recombinant Human EGF Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Recombinant Human EGF: by Application(USD Million)
  • Table 2. Recombinant Human EGF Pharmaceuticals , by Region USD Million (2014-2019)
  • Table 3. Recombinant Human EGF Cosmetics , by Region USD Million (2014-2019)
  • Table 4. Recombinant Human EGF Others , by Region USD Million (2014-2019)
  • Table 5. Recombinant Human EGF: by Category(USD Million)
  • Table 6. Recombinant Human EGF Heparin-binding EGF-like growth factor (HB-EGF) , by Region USD Million (2014-2019)
  • Table 7. Recombinant Human EGF Amphiregulin (AR) , by Region USD Million (2014-2019)
  • Table 8. Recombinant Human EGF Epiregulin (EPR) , by Region USD Million (2014-2019)
  • Table 9. Recombinant Human EGF Transforming Growth Factor-α (TGF-α) , by Region USD Million (2014-2019)
  • Table 10. Recombinant Human EGF Others , by Region USD Million (2014-2019)
  • Table 11. Recombinant Human EGF: by Indication(USD Million)
  • Table 12. Recombinant Human EGF Wound Healing , by Region USD Million (2014-2019)
  • Table 13. Recombinant Human EGF Gastrointestinal Ulceration , by Region USD Million (2014-2019)
  • Table 14. Recombinant Human EGF Brain Tumor Therapy , by Region USD Million (2014-2019)
  • Table 15. Recombinant Human EGF Others , by Region USD Million (2014-2019)
  • Table 16. Recombinant Human EGF: by Form(USD Million)
  • Table 17. Recombinant Human EGF Lyophilized Powder , by Region USD Million (2014-2019)
  • Table 18. Recombinant Human EGF Liquid , by Region USD Million (2014-2019)
  • Table 19. Recombinant Human EGF Others , by Region USD Million (2014-2019)
  • Table 20. Recombinant Human EGF: by Purity(USD Million)
  • Table 21. Recombinant Human EGF 98% SDS-PAGE , by Region USD Million (2014-2019)
  • Table 22. Recombinant Human EGF 95%-98% SDS-PAGE , by Region USD Million (2014-2019)
  • Table 23. Recombinant Human EGF <95% SDS-PAGE , by Region USD Million (2014-2019)
  • Table 24. South America Recombinant Human EGF, by Country USD Million (2014-2019)
  • Table 25. South America Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 26. South America Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 27. South America Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 28. South America Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 29. South America Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 30. Brazil Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 31. Brazil Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 32. Brazil Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 33. Brazil Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 34. Brazil Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 35. Argentina Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 36. Argentina Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 37. Argentina Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 38. Argentina Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 39. Argentina Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 40. Rest of South America Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 41. Rest of South America Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 42. Rest of South America Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 43. Rest of South America Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 44. Rest of South America Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 45. Asia Pacific Recombinant Human EGF, by Country USD Million (2014-2019)
  • Table 46. Asia Pacific Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 47. Asia Pacific Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 48. Asia Pacific Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 49. Asia Pacific Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 50. Asia Pacific Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 51. China Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 52. China Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 53. China Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 54. China Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 55. China Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 56. Japan Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 57. Japan Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 58. Japan Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 59. Japan Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 60. Japan Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 61. India Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 62. India Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 63. India Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 64. India Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 65. India Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 66. South Korea Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 67. South Korea Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 68. South Korea Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 69. South Korea Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 70. South Korea Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 71. Taiwan Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 72. Taiwan Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 73. Taiwan Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 74. Taiwan Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 75. Taiwan Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 76. Australia Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 77. Australia Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 78. Australia Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 79. Australia Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 80. Australia Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 81. Rest of Asia-Pacific Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 82. Rest of Asia-Pacific Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 83. Rest of Asia-Pacific Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 84. Rest of Asia-Pacific Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 85. Rest of Asia-Pacific Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 86. Europe Recombinant Human EGF, by Country USD Million (2014-2019)
  • Table 87. Europe Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 88. Europe Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 89. Europe Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 90. Europe Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 91. Europe Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 92. Germany Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 93. Germany Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 94. Germany Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 95. Germany Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 96. Germany Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 97. France Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 98. France Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 99. France Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 100. France Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 101. France Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 102. Italy Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 103. Italy Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 104. Italy Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 105. Italy Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 106. Italy Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 107. United Kingdom Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 108. United Kingdom Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 109. United Kingdom Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 110. United Kingdom Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 111. United Kingdom Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 112. Netherlands Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 113. Netherlands Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 114. Netherlands Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 115. Netherlands Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 116. Netherlands Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 117. Rest of Europe Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 118. Rest of Europe Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 119. Rest of Europe Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 120. Rest of Europe Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 121. Rest of Europe Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 122. MEA Recombinant Human EGF, by Country USD Million (2014-2019)
  • Table 123. MEA Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 124. MEA Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 125. MEA Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 126. MEA Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 127. MEA Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 128. Middle East Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 129. Middle East Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 130. Middle East Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 131. Middle East Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 132. Middle East Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 133. Africa Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 134. Africa Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 135. Africa Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 136. Africa Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 137. Africa Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 138. North America Recombinant Human EGF, by Country USD Million (2014-2019)
  • Table 139. North America Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 140. North America Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 141. North America Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 142. North America Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 143. North America Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 144. United States Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 145. United States Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 146. United States Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 147. United States Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 148. United States Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 149. Canada Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 150. Canada Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 151. Canada Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 152. Canada Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 153. Canada Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 154. Mexico Recombinant Human EGF, by Application USD Million (2014-2019)
  • Table 155. Mexico Recombinant Human EGF, by Category USD Million (2014-2019)
  • Table 156. Mexico Recombinant Human EGF, by Indication USD Million (2014-2019)
  • Table 157. Mexico Recombinant Human EGF, by Form USD Million (2014-2019)
  • Table 158. Mexico Recombinant Human EGF, by Purity USD Million (2014-2019)
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Recombinant Human EGF: by Application(USD Million)
  • Table 170. Recombinant Human EGF Pharmaceuticals , by Region USD Million (2022-2027)
  • Table 171. Recombinant Human EGF Cosmetics , by Region USD Million (2022-2027)
  • Table 172. Recombinant Human EGF Others , by Region USD Million (2022-2027)
  • Table 173. Recombinant Human EGF: by Category(USD Million)
  • Table 174. Recombinant Human EGF Heparin-binding EGF-like growth factor (HB-EGF) , by Region USD Million (2022-2027)
  • Table 175. Recombinant Human EGF Amphiregulin (AR) , by Region USD Million (2022-2027)
  • Table 176. Recombinant Human EGF Epiregulin (EPR) , by Region USD Million (2022-2027)
  • Table 177. Recombinant Human EGF Transforming Growth Factor-α (TGF-α) , by Region USD Million (2022-2027)
  • Table 178. Recombinant Human EGF Others , by Region USD Million (2022-2027)
  • Table 179. Recombinant Human EGF: by Indication(USD Million)
  • Table 180. Recombinant Human EGF Wound Healing , by Region USD Million (2022-2027)
  • Table 181. Recombinant Human EGF Gastrointestinal Ulceration , by Region USD Million (2022-2027)
  • Table 182. Recombinant Human EGF Brain Tumor Therapy , by Region USD Million (2022-2027)
  • Table 183. Recombinant Human EGF Others , by Region USD Million (2022-2027)
  • Table 184. Recombinant Human EGF: by Form(USD Million)
  • Table 185. Recombinant Human EGF Lyophilized Powder , by Region USD Million (2022-2027)
  • Table 186. Recombinant Human EGF Liquid , by Region USD Million (2022-2027)
  • Table 187. Recombinant Human EGF Others , by Region USD Million (2022-2027)
  • Table 188. Recombinant Human EGF: by Purity(USD Million)
  • Table 189. Recombinant Human EGF 98% SDS-PAGE , by Region USD Million (2022-2027)
  • Table 190. Recombinant Human EGF 95%-98% SDS-PAGE , by Region USD Million (2022-2027)
  • Table 191. Recombinant Human EGF <95% SDS-PAGE , by Region USD Million (2022-2027)
  • Table 192. South America Recombinant Human EGF, by Country USD Million (2022-2027)
  • Table 193. South America Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 194. South America Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 195. South America Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 196. South America Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 197. South America Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 198. Brazil Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 199. Brazil Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 200. Brazil Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 201. Brazil Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 202. Brazil Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 203. Argentina Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 204. Argentina Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 205. Argentina Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 206. Argentina Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 207. Argentina Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 208. Rest of South America Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 209. Rest of South America Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 210. Rest of South America Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 211. Rest of South America Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 212. Rest of South America Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 213. Asia Pacific Recombinant Human EGF, by Country USD Million (2022-2027)
  • Table 214. Asia Pacific Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 215. Asia Pacific Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 216. Asia Pacific Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 217. Asia Pacific Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 218. Asia Pacific Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 219. China Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 220. China Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 221. China Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 222. China Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 223. China Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 224. Japan Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 225. Japan Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 226. Japan Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 227. Japan Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 228. Japan Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 229. India Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 230. India Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 231. India Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 232. India Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 233. India Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 234. South Korea Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 235. South Korea Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 236. South Korea Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 237. South Korea Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 238. South Korea Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 239. Taiwan Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 240. Taiwan Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 241. Taiwan Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 242. Taiwan Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 243. Taiwan Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 244. Australia Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 245. Australia Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 246. Australia Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 247. Australia Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 248. Australia Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 249. Rest of Asia-Pacific Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 250. Rest of Asia-Pacific Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 251. Rest of Asia-Pacific Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 252. Rest of Asia-Pacific Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 253. Rest of Asia-Pacific Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 254. Europe Recombinant Human EGF, by Country USD Million (2022-2027)
  • Table 255. Europe Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 256. Europe Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 257. Europe Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 258. Europe Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 259. Europe Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 260. Germany Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 261. Germany Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 262. Germany Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 263. Germany Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 264. Germany Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 265. France Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 266. France Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 267. France Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 268. France Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 269. France Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 270. Italy Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 271. Italy Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 272. Italy Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 273. Italy Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 274. Italy Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 275. United Kingdom Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 276. United Kingdom Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 277. United Kingdom Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 278. United Kingdom Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 279. United Kingdom Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 280. Netherlands Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 281. Netherlands Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 282. Netherlands Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 283. Netherlands Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 284. Netherlands Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 285. Rest of Europe Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 286. Rest of Europe Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 287. Rest of Europe Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 288. Rest of Europe Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 289. Rest of Europe Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 290. MEA Recombinant Human EGF, by Country USD Million (2022-2027)
  • Table 291. MEA Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 292. MEA Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 293. MEA Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 294. MEA Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 295. MEA Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 296. Middle East Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 297. Middle East Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 298. Middle East Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 299. Middle East Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 300. Middle East Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 301. Africa Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 302. Africa Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 303. Africa Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 304. Africa Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 305. Africa Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 306. North America Recombinant Human EGF, by Country USD Million (2022-2027)
  • Table 307. North America Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 308. North America Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 309. North America Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 310. North America Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 311. North America Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 312. United States Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 313. United States Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 314. United States Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 315. United States Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 316. United States Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 317. Canada Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 318. Canada Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 319. Canada Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 320. Canada Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 321. Canada Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 322. Mexico Recombinant Human EGF, by Application USD Million (2022-2027)
  • Table 323. Mexico Recombinant Human EGF, by Category USD Million (2022-2027)
  • Table 324. Mexico Recombinant Human EGF, by Indication USD Million (2022-2027)
  • Table 325. Mexico Recombinant Human EGF, by Form USD Million (2022-2027)
  • Table 326. Mexico Recombinant Human EGF, by Purity USD Million (2022-2027)
  • Table 327. Research Programs/Design for This Report
  • Table 328. Key Data Information from Secondary Sources
  • Table 329. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Recombinant Human EGF: by Application USD Million (2014-2019)
  • Figure 5. Global Recombinant Human EGF: by Category USD Million (2014-2019)
  • Figure 6. Global Recombinant Human EGF: by Indication USD Million (2014-2019)
  • Figure 7. Global Recombinant Human EGF: by Form USD Million (2014-2019)
  • Figure 8. Global Recombinant Human EGF: by Purity USD Million (2014-2019)
  • Figure 9. South America Recombinant Human EGF Share (%), by Country
  • Figure 10. Asia Pacific Recombinant Human EGF Share (%), by Country
  • Figure 11. Europe Recombinant Human EGF Share (%), by Country
  • Figure 12. MEA Recombinant Human EGF Share (%), by Country
  • Figure 13. North America Recombinant Human EGF Share (%), by Country
  • Figure 14. Global Recombinant Human EGF share by Players 2019 (%)
  • Figure 15. Global Recombinant Human EGF share by Players (Top 3) 2019(%)
  • Figure 16. Global Recombinant Human EGF share by Players (Top 5) 2019(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. FUJIFILM Irvine Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 19. FUJIFILM Irvine Scientific (United States) Revenue: by Geography 2019
  • Figure 20. PeproTech, Inc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. PeproTech, Inc (United Kingdom) Revenue: by Geography 2019
  • Figure 22. RandD Systems (Bio-Techne) (United States) Revenue, Net Income and Gross profit
  • Figure 23. RandD Systems (Bio-Techne) (United States) Revenue: by Geography 2019
  • Figure 24. Miltenyi Biotec (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Miltenyi Biotec (Germany) Revenue: by Geography 2019
  • Figure 26. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 27. Thermo Fisher Scientific (United States) Revenue: by Geography 2019
  • Figure 28. Abcam PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. Abcam PLC (United Kingdom) Revenue: by Geography 2019
  • Figure 30. STEMCELL Technologies (Canada) Revenue, Net Income and Gross profit
  • Figure 31. STEMCELL Technologies (Canada) Revenue: by Geography 2019
  • Figure 32. RayBiotech, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 33. RayBiotech, Inc (United States) Revenue: by Geography 2019
  • Figure 34. Prospec-Tany (Israel) Revenue, Net Income and Gross profit
  • Figure 35. Prospec-Tany (Israel) Revenue: by Geography 2019
  • Figure 36. ScienCell Research Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 37. ScienCell Research Laboratories (United States) Revenue: by Geography 2019
  • Figure 38. Global Recombinant Human EGF: by Application USD Million (2022-2027)
  • Figure 39. Global Recombinant Human EGF: by Category USD Million (2022-2027)
  • Figure 40. Global Recombinant Human EGF: by Indication USD Million (2022-2027)
  • Figure 41. Global Recombinant Human EGF: by Form USD Million (2022-2027)
  • Figure 42. Global Recombinant Human EGF: by Purity USD Million (2022-2027)
  • Figure 43. South America Recombinant Human EGF Share (%), by Country
  • Figure 44. Asia Pacific Recombinant Human EGF Share (%), by Country
  • Figure 45. Europe Recombinant Human EGF Share (%), by Country
  • Figure 46. MEA Recombinant Human EGF Share (%), by Country
  • Figure 47. North America Recombinant Human EGF Share (%), by Country
List of companies from research coverage that are profiled in the study
  • FUJIFILM Irvine Scientific (United States)
  • PeproTech, Inc (United Kingdom)
  • RandD Systems (Bio-Techne) (United States)
  • Miltenyi Biotec (Germany)
  • Thermo Fisher Scientific (United States)
  • Abcam PLC (United Kingdom)
  • STEMCELL Technologies (Canada)
  • RayBiotech, Inc (United States)
  • Prospec-Tany (Israel)
  • ScienCell Research Laboratories (United States)
Additional players considered in the study are as follows:
EnQuire Bio (United States) , Tonbo Biosciences (United States) , BioVision, Inc (United States) , Abm Inc (United States) , Cell Guidance Systems (United Kingdom) , Sino Biological (China) , Axol Bioscience (United Kingdom)
Select User Access Type

Key Highlights of Report


Aug 2022 199 Pages 60 Tables Base Year: 2019 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Recombinant Human EGF Quantitative research analysis
Global Recombinant Human EGF Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Recombinant Human EGF Market is heading robustly to achieve a new growth cycle.
The Concentration Rate of Global Recombinant Human EGF market is dominated by United States Players and may generate healthy valuation by 2027.
  • Growth in Biotechnology Industry
  • Prevalence of Chronic Injuries
dominated the Recombinant Human EGF market. This is attributable to growing trend of "High Investments in Biotech R&D"

Know More About Global Recombinant Human EGF Report?

Have a Query? Click Here

Other Related Reports

Genetic Ancestry Testing Comprehensive Study by Type (Y Chromosome Testing, Mitochondrial DNA Testing, Single Nucleotide Polymorphism Testing), Service (Online Testing, Offline Testing) Players and R...
$ 3500
Ion Indicator Comprehensive Study by Type (Zinc Indicators, Calcium Indicators, Sodium Indicators, Potassium Indicators, Chloride Indicators, Membrane Potential Indicators, PH Indicators), Applicatio...
$ 3350
Cryogenic Storage Chest Freezers Comprehensive Study by Type (-20°C~-80°C, <-80°C), Application (Research Institutes and Universities, Life sciences and Pharmaceuticals, Others), Distribution Channel...
$ 3350
Cellular Health Assays Comprehensive Study by Type (ADME Tox Assays, 3D Cell Culture, Apoptosis Assays, Autophagy Detection, Inflammation Assays, Others), Application (Biomedical Research, Drug-disco...
$ 3650
Plant Breeding Comprehensive Study by Application (Disease Resistance, Higher Yield, Seed Improvement, Other), Industry Verticals (Agriculture, Horticulture, Tropical Plant Research), Plants (Oilseed...
$ 3750
DNA Extraction Kit Comprehensive Study by Type (Tissue DNA Extraction Kits, Blood DNA Extraction Kits, Cell DNA Extraction Kits, Forensic DNA Extraction Kits, Bacterial DNA Extraction Kits, Viral DNA...
$ 2800